Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
DUPRO steering committee and PROTECT Investigators
Untersuchen Sie die Forschungsthemen von „Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial“. Zusammen bilden sie einen einzigartigen Fingerprint.